7/19/2019  4:54:04 PM Chg. -8.60 Volume Bid4:59:38 PM Ask4:58:30 PM Market Capitalization Dividend Y. P/E Ratio
252.10DKK -3.30% 34,223
Turnover: 8.75 mill.
248.00Bid Size: 178 253.90Ask Size: 1,684 50.43 bill.DKK 4.73% 12.91

Business description

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain disease. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
 

Management board & Supervisory board

CEO
Dr. Deborah Dunsire
Management board
Anders Götzsche, Dr. Johan Luthman, Jacob Tolstrup, Keld Flintholm Jørgensen, Lars Bang, Peter Anastasiou
Supervisory board
Lars Rasmussen, Henrik Andersen, Henrik Sindal Jensen, Jeffrey Berkowitz, Jeremy M. Levin, Lars Holmqvist, Lene Skole-Sørensen, Ludovic Tranholm Otterbein, Rikke Kruse Andreasen
 

Company data

Name: H. Lundbeck A/S
Address: Ottiliavej 9,DK-2500 Valby
Phone: +45-3630-1311
Fax: +45-3630-1940
E-mail: information@lundbeck.com
Internet: www.lundbeck.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 31.00%
IPO date: -

Investor relations

Name: Palle Holm Olesen
IR phone: +45-3643-2426
IR Fax: -
IR e-mail: investor@lundbeck.com

Company calendar

CW 33 | 8/14/2019 Interim Report 2nd Quarter/6 Months
CW 45 | 11/5/2019 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Lundbeckfonden
 
69.00%
Freefloat
 
31.00%